FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference

SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating pamrevlumab, a monoclonal antibody to connective tissue growth factor (CTGF) in non-ambulatory subjects with Duchenne muscular dystrophy at the Parent Project Muscular Dystrophy (PPMD) 2019 Annual Conference in Orlando, Florida on Friday, June 28, 2019.
Presentation slides from the PPMD 2019 Annual Conference will be available on the investor section of the FibroGen corporate website at www.fibrogen.com.
About Pamrevlumab
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit…

Source: Original Article